Compare MTH & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTH | LEGN |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.9B |
| IPO Year | 1988 | 2020 |
| Metric | MTH | LEGN |
|---|---|---|
| Price | $66.56 | $22.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $82.75 | $69.58 |
| AVG Volume (30 Days) | 772.1K | ★ 2.3M |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.50 | N/A |
| Revenue | ★ $6,043,594,000.00 | $909,045,000.00 |
| Revenue This Year | N/A | $68.83 |
| Revenue Next Year | $5.61 | $51.27 |
| P/E Ratio | $8.88 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $59.27 | $21.19 |
| 52 Week High | $84.74 | $45.30 |
| Indicator | MTH | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 34.78 |
| Support Level | $64.85 | $21.19 |
| Resistance Level | $73.09 | $28.97 |
| Average True Range (ATR) | 1.71 | 1.12 |
| MACD | -0.72 | 0.12 |
| Stochastic Oscillator | 19.13 | 23.01 |
Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising ten states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Utah. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the homebuilding segment.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.